Showing results (31-40 of 43) with videos related to
Sort By:
Pageof 5
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2008
Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancerPanos M Fidias, Shaker R Dakhil, Alan P Lyss, et al.Lung Cancer (Amsterdam, Netherlands)|September 6, 2012
Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancerDavid R Spigel, F Anthony Greco, David M Waterhouse, et al.JCO Oncology Practice|January 6, 2021
Recommendations to Streamline and Standardize Clinical Trial Site Feasibility Assessments: An ASCO Research StatementDax Kurbegov, Patricia Hurley, David M Waterhouse, et al.The Oncologist|August 18, 2019
A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE TrialDavid R Spigel, Dianna L Shipley, David M Waterhouse, et al.The Oncologist|September 23, 2017
A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER TrialAndrew H Ko, Patrick B Murphy, James D Peyton, et al.JCO Precision Oncology|April 22, 2026
Biomarker Testing Rates and Patterns in Patients With Metastatic Non-Small Cell Lung Cancer: A Prospective, Observational Study in Community PracticesMakenzi Evangelist, Bo Wang, James E Butrynski, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 24, 2019
Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)David R Spigel, Michael McCleod, Robert M Jotte, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 26, 2023
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or ChemotherapyKai He, David Berz, Shirish M Gadgeel, et al.Lung Cancer (Amsterdam, Netherlands)|September 20, 2024
Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutationDavid M Waterhouse, Sacha Rothschild, Christophe Dooms, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2007
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT InvestigatorsTomasz M Beer, Christopher W Ryan, Peter M Venner, et al.Pageof 5